US Hemophilia Treatment Market

ID: MRFR/Pharma/15123-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026
US Hemophilia Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Prophylactic Treatment, On-Demand Treatment, Gene Therapy, Desmopressin, Factor Replacement Therapy), By Hemophilia Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), By Administration Route (Intravenous, Subcutaneous, Oral) and By End Users (Hospitals, Specialty Clinics, Home Care Settings) - Growth Outlook & Industry Forecast 2025 To 2035
US Hemophilia Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.25%
2024 Market Size$ 2,604 Million
2025 Market Size$ 2,714.67 Million
2035 Market Size$ 4,116.84 Million
Key Players
Baxter International
Boehringer Ingelheim
CSL Behring
Novo Nordisk
Pfizer
Roche
Trends
  • Emergence of Gene Therapies
  • Regulatory Changes and Accelerated Approvals
  • Personalized Medicine Approaches
Opportunities
  • Rising Prevalence of Hemophilia
  • Advancements in Treatment Technologies
  • Increased Funding for Hemophilia Research
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Treatment Type (USD Million)
      1. 4.1.1 Prophylactic Treatment
      2. 4.1.2 On-Demand Treatment
      3. 4.1.3 Gene Therapy
      4. 4.1.4 Desmopressin
      5. 4.1.5 Factor Replacement Therapy
    2. 4.2 Construction, BY Hemophilia Type (USD Million)
      1. 4.2.1 Hemophilia A
      2. 4.2.2 Hemophilia B
      3. 4.2.3 Von Willebrand Disease
    3. 4.3 Construction, BY Administration Route (USD Million)
      1. 4.3.1 Intravenous
      2. 4.3.2 Subcutaneous
      3. 4.3.3 Oral
    4. 4.4 Construction, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Specialty Clinics
      3. 4.4.3 Home Care Settings
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Baxter International (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 CSL Behring (AU)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novo Nordisk (DK)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Roche (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Takeda Pharmaceutical (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Octapharma (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY HEMOPHILIA TYPE
    4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY HEMOPHILIA TYPE, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY HEMOPHILIA TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Hemophilia Treatment Market Segmentation

US Hemophilia Treatment Market By Treatment Type (USD Million, 2025-2035)

  • Prophylactic Treatment
  • On-Demand Treatment
  • Gene Therapy
  • Desmopressin
  • Factor Replacement Therapy

US Hemophilia Treatment Market By Hemophilia Type (USD Million, 2025-2035)

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease

US Hemophilia Treatment Market By Administration Route (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral

US Hemophilia Treatment Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Home Care Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.